http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006119673-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_373711468f5420207f0bc6e771b8538e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e562831ac734fa7ef92348ef1fdee789
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94
filingDate 2005-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_931da61416c4520ce90912d984424768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da34265952643767c2fc57f34307d2af
publicationDate 2006-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2006119673-A1
titleOfInvention The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
abstract Provided are quinazoline derivatives of the compound (I), and its preparation process and application as a medicine of inhibit tumor growth. The group X, Y, Z, R1, R2, R3, R4 of compound (I) are defined in the description. Compounds of the invention can specially inhibit tyrosine kinase activity, inhibit the activity of two high-affinity receptors of VEGF, adjust VEGF secretion, thus to have to achieve the purpose of treating malignant tumor.
priorityDate 2005-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0635498-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128339009
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397482
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9210

Total number of triples: 20.